In order to improve the company's environmental benefits, economic benefits and reduce pollutant emissions, in accordance with the notice of the Shaanxi Provincial Department of Ecology and Environment and the Shaanxi Provincial Development and Reform Commission on the issuance of the "Shaanxi Provincial Cleaner Production Audit 2021 Annual Work Plan" (Shaanxi Environmental Science and Finance Letter [2021] No. 23), our company will start the cleaner production audit work in an all-round way from the end of May 2022.
In accordance with the requirements of the "Cleaner Production Promotion Law of the People's Republic of China" and the "Cleaner Production Auditing Measures", we now announce to the public the use of raw materials, resources and energy, and pollution discharge before our company's audit. All people are requested to supervise our company's implementation of cleaner production audits.
1.The basic situation of company
1) Company name: Xi’an wanlong pharmaceutical Co., Ltd.
2) Legal representative: Chen Qiulin
3)Address: No.2, Yongan Road, Yangling Agricultural Hi-Tech Industries Demonstration Zone, Shaanxi, China 712100
4) Production scale: 4 API production lines, 2 large injection production lines, 1 small water injection production line, 2 solid FDF production lines, and 1 water extraction production line.
5) Category: Pharmaceutical Manufacturing
6) Main Products: FDFs: Ornidazole Capsule, Gatifloxacin Tablet, Mixed Nucleoside Tablet, Ubenimex Capsule, Fexofenadine Hydrochloride Granule, Fexofenadine Hydrochloride Tablet, Epalrestat Tablet, Ubenimex Tablet, Sodium Bicarbonate Ringer's Injection, Sodium Acetate Glucose Injection, L-Alanyl-L-glutamine Injection, Gatifloxacin and Sodium Chloride Injection, Ornidazole and Sodium Chloride Injection, Compound Dextran 40 Injection, Moxifloxacin Glucose Injection, Tirofiban Hydrochloride and Sodium Chloride Injection, Compound Electrolyte Glucose (IV) Injection, Gucixiaotong Capsule, Zaorenanshen Granule, Gujingmaisiha Tablet, Wulongsan Powder and Xiaokeling capsule.
APIs: Ubenimex, L-malic acid, Moxifloxacin Hydrochloride, Tirofiban Hydrochloride, Fexofenadine Hydrochloride, Calcium Chloride, Magnesium Chloride , Sodium Acetate, L-Alanyl-L-glutamine, Ornidazole, Mixed nucleoside, Dextran.
2.Raw materials and resource and energy consumption
The main resources and energy consumed by our company in the production process in 2021 are: 7,805,844 kWh of electricity, 61,787 cubic meters of natural gas, 170,866 tons of water, and 22,357 tons of steam.
3.Sewage before the audit
The company's environmental monitoring report data in the fourth quarter of 2021.
4.Implementation of environmental risk prevention and control measures in accordance with the law
According to the requirements of documents such as "Interim Measures for the Management of Emergency Plans for Environmental Emergencies", "Administrative Measures for the Filing of Emergency Response Plans for Environmental Emergencies of Enterprises and Institutions", the company regularly prepares and records "Corporate Environmental Emergency Response Plan", and the record code is 610403- 2022-017-M.
The "Corporate Environmental Emergency Response Plan" establishes an environmental risk hidden danger screening and prevention control system, replenishes emergency materials in a timely manner according to daily consumption, and stores them in designated locations. Arrange special personnel for management and inspection to ensure that the facilities and materials are in good condition and effective, and ready to use.
5.Contact information
Auditing company: Xi'an Wanlong Pharmaceutical Co., Ltd.
Contact person: Jing Honggang
Tel: 13991906407
Consulting agency: Xi'an Gaiya Environmental Protection Technology Co., Ltd.
Contact person: Song Jinwei
Tel: 13227022116
Xi'an Wanlong Pharmaceutical Co., Ltd.
August 1, 2022